A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma - Ko, AH; Bekaii-Saab, T; van Ziffle, J (Clin Cancer Res, 2016)
et al.